Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Determining a Company’s Value - Old School

<< Previous

Bullboard Posts

Next >>

Comment by Rumpl3StiltSkinon Apr 25, 2022 9:12am

231 Views

Post# 34628428

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Determining a Company’s Value - Old School

Yep Slayer, TLT has mentioned most of those cancers as eventual targets, I think the consternation is how long it is taking. Covid 19 has thrown this Phase 2 a curve, and perhaps also a lifeline? I hope so...

CancerSlayer wrote:

Rumpl3StiltSkin wrote: Good points Fred,

I hope it is just they're focused now on NMIBC and getting us to home plate.

fredgoodwinson wrote: Rumpl - long been here for the prospective treatment of a range of cancers both by TLD-1433 and other of Sherri`s metal-based compounds which in terms of unconditional exclusivity may effectively mean Rutherrin.

There now looks to be no prospect of addressing any further cancers in this way in the foreseeable future and this is bitterly regretted - all the more so as Roswell were giving the most serious consideration to the use of TLD-1433 in lung cancer and mesothelioma.

Would TLT have the slightest difficulty in finding partners if Rutherrin has the ability to treat deep seated cancers non-invasively via low dose x-ray as repeatedly suggested in their newsletters?

Will not guess as to why after so many years`preclinical due diligence the Company so quickly rowed back from using Rutherrin in humans but with the possible exception of the present Trial you are certainly right in saying that TLT`s ACT hasn`t gone anywhere.

Agree rumpl...and an FDA approval for bcg-unresponsive NMIBC should lay a pretty solid foundation for not only future approvals, but also pave the way for the off-label use of TLD 1433 in place of Photofrin, which is currently FDA approved for multiple indications (esophageal cancer, endobronchial NSCLC & high-grade dysplasia in Barrett's esophagus = a prevalent precancerous condition). This indication list does not include Photofrin's off-label uses (i.e. head & neck/oral cancers).

There are multiple other globally approved photosensitizers in use that cover additional indications (I.e. skin cancer, actinic keratosis, glioma, breast cancer, etc.) that could also provide additional opportunities for use of TLD 1433.

Simply put, an approval for BCG-unresponsive NMIBC could end up being the master key that opens multiple doors...each one bigger than the next in terms of total earnings. Good luck...